Light Chain Bioscience | Novimmune Email Formats

Biotechnology Research • Plan-les-Ouates, Geneva, Switzerland • 51-100 Employees

Light Chain Bioscience | Novimmune Email Formats

Light Chain Bioscience | Novimmune uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@lightchainbio.com), used 100% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@lightchainbio.com	100%

Key Contacts at Light Chain Bioscience | Novimmune

Nicolas Fischer

Chief Executive Officer

Krzysztof Masternak

Director, Drug Discovery

Nathalie Muller

Corporate Secretary, Director Administration And Legal Affairs

Bernard Mach

Founder

Company overview

Headquarters	Chemin du Pré-Fleuri 15, 3ième Étage, Plan-les-Ouates, Genève 1228, CH
Phone number	+7758724444
Websites	lightchainbio.com novimmune.com
NAICS	541714
SIC	873
Keywords	Immunology, Clinical Development, Bispecific Antibody Drugs, Next-Generation Antibody Drug Discovery
Founded	1998
Employees	51-100
Socials

About Light Chain Bioscience | Novimmune

NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Senior

Employees by Department

Light Chain Bioscience | Novimmune has 30 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore Light Chain Bioscience | Novimmune's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2016-02-11	6	$29,800,000

Funding Insights

$29,800,000

Total funding amount

$29,800,000

Most recent funding amount

Number of funding rounds

Light Chain Bioscience | Novimmune Tech Stack

Discover the technologies and tools that power Light Chain Bioscience | Novimmune's digital infrastructure, from frameworks to analytics platforms.

Joomla

CMS

UIKit

UI frameworks

jQuery

JavaScript libraries

Nginx

Reverse proxies

PHP

Programming languages

Open Graph

Miscellaneous

Elfsight

Widgets

Helix Ultimate

Web frameworks

Bootstrap

UI frameworks

Frequently asked questions

Light Chain Bioscience | Novimmune is located in Plan-les-Ouates, Geneva, CH.

You can reach Light Chain Bioscience | Novimmune at +7758724444.

Light Chain Bioscience | Novimmune was founded in 1998, making it 28 years old. The company has established itself as a significant player in its industry over this time.

Light Chain Bioscience | Novimmune has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Light Chain Bioscience | Novimmune has raised a total of $29,800,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.